Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 56, 2022 - Issue 2
Journal homepage
121
Views
0
CrossRef citations to date
0
Altmetric
Articles

Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting

Carsten Niedera Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway;b Faculty of Health Sciences, Department of Clinical Medicine, UiT- The Arctic University of Norway, Tromsø, NorwayCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1592-2908
ORCID Icon,
Luka Stanisavljevica Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
,
Astrid Dalhauga Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway;b Faculty of Health Sciences, Department of Clinical Medicine, UiT- The Arctic University of Norway, Tromsø, Norway
&
Ellinor Hauklanda Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway;b Faculty of Health Sciences, Department of Clinical Medicine, UiT- The Arctic University of Norway, Tromsø, Norway;c Faculty of Health Sciences, SHARE – Center for Resilience in Healthcare, Department of Quality and Health Technology, University of Stavanger, Stavanger, NorwayORCID Iconhttps://orcid.org/0000-0002-5697-2218
ORCID Icon
Pages 114-118 | Received 03 Nov 2021, Accepted 03 Jan 2022, Published online: 17 Feb 2022

References

  • Kaipia A, Riikonen J. Contemporary and past challenges of prostate cancer diagnostics. Scand J Urol. 2017;51(3):193–201.
  • Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–282.
  • Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
  • Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087.
  • Tucci M, Bertaglia V, Vignani F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(4):563–573.
  • Levit LA, Byatt L, Lyss AP, et al. Closing the rural cancer care gap: three institutional approaches. JCO Oncol Pract. 2020;16(7):422–430.
  • Charlton M, Schlichting J, Chioreso C, et al. Challenges of rural cancer care in the United States. Oncology. 2015;29(9):633–640.
  • Baade PD, Yu XQ, Smith DP, et al. Geographic disparities in prostate cancer outcomes-review of international patterns. Asian Pac J Cancer Prev. 2015;16(3):1259–1275.
  • Nieder C, Dalhaug A, Haukland E. Feasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care setting. Scand J Urol. 2020;54(2):110–114.
  • Azad AA, Tran B, Davis ID, et al. Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. Intern Med J. 2021. doi: https://doi.org/10.1111/imj.15288.
  • Rulach RJ, McKay S, Neilson S, et al. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU Int. 2018;121(2):268–274.
  • James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177.
  • Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and Meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–256. Erratum in: Lancet Oncol. 2016;17:e46.
  • Rydzewska LHM, Burdett S, Vale CL, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88–101.
  • Adashek JJ, Reed JP, Tandon A, et al. Combination androgen receptor inhibition and docetaxel in metastatic castration-sensitive prostate cancer: the next step in first-line treatment? Clin Genitourin Cancer. 2020;18(6):425–428.
  • Vigneswaran HT, Warnqvist A, Andersson TML, et al. Real world treatment utilization patterns in patients with castration-resistant prostate cancer. Scand J Urol. 2021;55(4):299–306.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.